Last reviewed · How we verify
Autologous BMDC implantation at the venous ulcer
Autologous BMDC implantation at the venous ulcer is a Biologic drug developed by Hospital de Clínicas Dr. Manuel Quintela. It is currently in Phase 1 development.
At a glance
| Generic name | Autologous BMDC implantation at the venous ulcer |
|---|---|
| Sponsor | Hospital de Clínicas Dr. Manuel Quintela |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous BMDC implantation at the venous ulcer CI brief — competitive landscape report
- Autologous BMDC implantation at the venous ulcer updates RSS · CI watch RSS
- Hospital de Clínicas Dr. Manuel Quintela portfolio CI
Frequently asked questions about Autologous BMDC implantation at the venous ulcer
What is Autologous BMDC implantation at the venous ulcer?
Autologous BMDC implantation at the venous ulcer is a Biologic drug developed by Hospital de Clínicas Dr. Manuel Quintela.
Who makes Autologous BMDC implantation at the venous ulcer?
Autologous BMDC implantation at the venous ulcer is developed by Hospital de Clínicas Dr. Manuel Quintela (see full Hospital de Clínicas Dr. Manuel Quintela pipeline at /company/hospital-de-cl-nicas-dr-manuel-quintela).
What development phase is Autologous BMDC implantation at the venous ulcer in?
Autologous BMDC implantation at the venous ulcer is in Phase 1.